New Research Shows Positive Clinical Outcomes With Thoracic & Lumbar Spinal Patients
New Research Shows Positive Clinical Outcomes With Thoracic & Lumbar Spinal Patients
PR Newswire
PENSACOLA, Fla., July 23, 2026
New observational research from Regenative Labs involving 117 patients demonstrates promising improvements in reported pain and functional scores following the application of cryopreserved human umbilical cord tissue allografts for thoracic and lumbar spinal defects.
PENSACOLA, Fla., July 23, 2026 /PRNewswire/ -- A recent observational investigation, featured in the peer-reviewed journal Biomedicines, analyzed patient-reported findings from 117 individuals. These patients had undergone applications of cryopreserved human umbilical cord tissue allograft for issues affecting their thoracic and lumbar paraspinal muscles and entheses. The data for this study was collected from an observational repository overseen by Regenative Labs, an FDA-registered company based in Pensacola, Florida, known for manufacturing cryopreserved Wharton's Jelly allografts.
The study, "An Observational Study of Human Umbilical Cord Tissue Allografts for Paraspinal Muscle and Entheses Defects in the Thoracic and Lumbar Regions," was authored by Conrad Tamea, Jeff Buchalter, Jason Capra, Tracie Gilliland, Naomi Lambert, Alexis Lee, and Tyler Barrett.
The full study is available open access from Biomedicines under a Creative Commons Attribution (CC BY) license. To read the study and learn more about birth tissue sciences, visit https://doi.org/10.3390/biomedicines14051030 .
Across 11 participating clinics, 117 patients with imaging-confirmed paraspinal degeneration received one to three applications of a cryopreserved umbilical cord tissue allograft. Outcomes were tracked using the Numeric Pain Rating Scale (NPRS), the Western Ontario and McMaster Universities Arthritis Index (WOMAC).
The authors reported reductions in average NPRS and WOMAC scores from the initial visit to the final visit across all application groups, with the multi-application groups showing statistically significant differences in several analyses. The authors reported that no adverse events or complications were observed during the study period.
Measure | Single application | Double application | Triple application |
NPRS | 6.54 to 4.65 | 4.41 to 3.17 | 4.75 to 2.00 |
WOMAC | 49.72 to 38.98 | 43.56 to 29.84 | 41.95 to 25.55 |
Mean patient-reported scores from initial to final visit, as reported by the authors. Lower NPRS and WOMAC scores indicate improvement. |
Human umbilical cord tissue contains a collagen-rich extracellular matrix. In the published discussion, the authors describe the structural similarity between this matrix and paraspinal connective tissue as a basis for using the allograft to supplement and support degenerated tissue in homologous locations.
"Our comprehensive analysis of the clinical data provides an essential framework for advancing the standards of regenerative medicine within the industry," said Tyler Barrett, Chief Executive Officer of Regenative Labs and a co-author of the study. "These findings add to the growing body of evidence supporting the use of cryopreserved umbilical cord tissue allografts and underscore our commitment to conducting transparent research that helps clinicians and patients make informed clinical decisions."
The publication of this data adds to Regenative Labs' growing body of peer-reviewed research and reflects the company's dedication to advancing scientific understanding of birth tissue allografts. By supporting the collection and analysis of real-world clinical data, Regenative Labs aims to contribute to evidence-based discussions surrounding regenerative medicine and help expand knowledge of potential clinical options for patients with missing or damaged musculoskeletal tissue.
Citation
Tamea C, Buchalter J, Capra J, Gilliland T, Lambert N, Lee A, Barrett T. An Observational Study of Human Umbilical Cord Tissue Allografts for Paraspinal Muscle and Entheses Defects in the Thoracic and Lumbar Regions. Biomedicines . 2026;14:1030. doi:10.3390/biomedicines14051030
Media Contact
Evan Dempsey
Marketing Director
Regenative Labs
800-891-3452 | Info@RegenativeLabs.com
SOURCE Regenative Labs
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
5 Stocks to Sell for Tax-Loss Harvesting
33 Undervalued Stocks to Buy Before the Market Shifts Again
Undervalued by 15%, This Utilities Stock Could Be an Unexpected AI Winner
United States